ADL Amdl,

TUSTIN, Calif. and PHOENIX, Feb. 8 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, with a wholly-owned pharmaceutical manufacturing subsidiary in China, announced today that its CEO, Gary Dreher, will present at the RedChip Small-Cap Investor Conference in Phoenix, Arizona, 1:15 p.m. Pacific on Monday, February 12, 2007. The Conference is at the Tempe Mission Palms Resort. Mr. Dreher will tell the potential investors about recent successes for the Company in China, including the introduction of Ondansetron Hydrochloride, with $2 billion in sales worldwide, for nausea caused by chemotherapy, radiation and other conditions, and the newly licensed products Lomefloxacin Aspartate and Levofloxacin, broad spectrum antibiotics, which have worldwide sales of more than $4.8 billion. "Jade Pharmaceuticals has access to the fastest growing pharmaceutical and consumer market in the world: China. Through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice ('CGMP') standards and we are anxious to tell these investors about Jade Pharmaceuticals' achievements," Mr. Dreher said. The RedChip Small-Cap Investor Conference will give top retail brokers, institutional brokers and fund managers the opportunity to listen to presentations from companies in a number of different industries. The Conference is available live on the Internet at http://www.modavox.com/events/redchip/0207/room1/ and for 90 days after the conference at http://www.redchip.com/ . RedChip is noted for its ability to bring together both professional and individual small-cap investors with superior small cap companies. "AMDL has an enormously compelling story to tell and we look forward to this opportunity," Mr. Dreher said. About AMDL AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at http://www.amdl.com/. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.modavox.com/events/redchip/0207/room1 Web site: http://http//www.redchip.com Web site: http://www.amdl.com/

Copyright